PEIJIA-B

9996
3.6504.70% ( -0.180 )
Delay Closed: Nov 16, 16:08:11

Overview

PEIJIA-B (9996)

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and ne...

Open
3.830
High
3.920
Low
3.650
Prev. Close
3.830
Volume
772.00K
Turnover
2.88M
Avg Price
3.737
Bid/Ask Ratio
92.59%
Amplitude
7.05%
52wk High
7.370
Volume Ratio
0.83
Turnover Ratio
0.11%
52wk Low
3.545
HK Mkt Cap
2.47B
Market CapHKD
2.47B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.240
EPSDynamic
-0.0258
EPSStatic
--
BVPS
3.13
P/B
1.17
HK Shares
676.96M
Dividend YieldTTM
--
DividendTTM
--
Shares
676.96M
Min lot size
1,000
Currency
HKD

PEIJIA-B Analyst Rating

View more

Forecast & Rating

Aug 27, 2026
Price forecast
HK$9.79168.09%
Forecast & RatingStrong buy
4analysts
  • Strong buy75.00%
  • Buy25.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Peijia Medical (9996.HK) opened low and rallied today, climbing from yesterday's close of HKD 4.100 to an intraday high of HKD 4.380 in the morning session before pulling back to close at HKD 4.320, up 5.37% from the previous close and breaking a recent downtrend. The rally was primarily driven by the company receiving NMPA approval for its TaurusTrio transcatheter aortic valve system, the first interventional treatment in China for aortic regurgitation, which sparked a revaluation of its product pipeline. Financially, operating revenue grew 19.57% YoY in Q4 2025 and 12.81% in Q3 2025, while net losses narrowed by over 10% in both quarters, pointing to gradual fundamental improvement. However, the current price of HKD 4.320 remains more than 53% below the 52-week high of HKD 9.36 and sits below the 60-day moving average of HKD 5.362, indicating a still-weak price position; the stock is down 29.41% year-to-date. Intraday turnover was light at only 673,000 shares, suggesting the rebound's sustainability requires further volume confirmation.

News